Finding a drug that can re-educate the body's confusion in lupus has proven a puzzler for biotech firms for years, and opinion is divided on which companies might be getting close to a fix for the devilish disease. Is there a way to teach the immune system the difference it once knew between foreign antigens and its own? (BioWorld Financial Watch)

Lpath Inc. closed the second tranche of an April private placement, for a total financing of $16.8 million to push its lead compound, the anti-angiogenic compound Sphingomab, into the clinic.(BioWorld Today)